1502 GMT - Novo Nordisk's early trial data of amycretin impresses on weight loss, with patients losing 22% of their body weight at the highest dose at 36 weeks, Barclays analysts write. "Novo shares are taking this well as this news finally breaks the tide of negative sentiment." Though it was a phase 1 study with a multi-part design and there is limited information on safety, the weight loss puts it on par with the best injectable data out there, Barclays says. Shares trade 11% higher at 643.80 Danish kroner.(dominic.chopping@wsj.com)
(END) Dow Jones Newswires
January 24, 2025 10:02 ET (15:02 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。